-
Vivani Medical secures $10M equity financing for semaglutide implant
-
Vivani Medical (VANI) Appoints Anthony Baldor as CFO
-
Vivani Medical (VANI) Files Form 10 Registration Statement for Planned Spin-Off of Cortigent Neurostimulation Business to Vivani Shareholders
-
Vivani Medical, Inc. (VANI) Misses Q1 EPS by 1c
-
Vivani Medical (VANI) and Okava Expand Collaboration to Develop OKV-119
-
H.C. Wainwright Reiterates Buy Rating on Vivani Medical, Inc. (VANI)
-
Vivani Medical, Inc. (VANI) Reports In-Line Q4 EPS
-
Vivani Medical (VANI) Announces 7.37M Share Offering at $1.12/sh
-
H.C. Wainwright Reiterates Buy Rating on Vivani Medical, Inc. (VANI)
-
Vivani Medical (VANI) Announces Positive Preclinical Weight Loss Data for NPM-139
-
Vivani Medical (VANI) Achieves First Implant and Full Enrollment in the First-in-Human Clinical Trial of GLP-1 Implant NPM-115 in Obese or Overweight Adults
-
H.C. Wainwright Reiterates Buy Rating on Vivani Medical, Inc. (VANI)
-
Vivani Medical (VANI) to Spin Off Cortigent Neurostimulation Business
-
H.C. Wainwright Reiterates Buy Rating on Vivani Medical, Inc. (VANI)
-
Vivani Medical (VANI) Announces Initiation of First in Human Clinical Trial with GLP-1 Implant in Obese and Overweight Individuals in Australia
-
Vivani Medical (VANI) Receives Regulatory Approval to Initiate First in Human Clinical Trial with GLP-1 Implant in Obese and Overweight Individuals in Australia
-
Vivani Medical (VANI) Announces Positive Preclinical Liver Fat Results with Miniature, Ultra Long-Acting GLP-1 Implant
-
Vivani Medical, Inc. (VANI) Tops Q2 EPS by 2c
-
Vivani Medical (VANI) Announces FDA Clears Investigational New Drug Application and Lifts Clinical Hold for NPM-119, a Miniature Long-Term Subdermal GLP-1 Drug Implant

